Table 18.
Individual animal clinical signs data on males at Phase II.
| Experimental Day |
||||||
|---|---|---|---|---|---|---|
| Day 1 |
Day 2 |
Day 3 |
||||
| Group No. | A # | Pre dose | Post dose | Pre dose | Post dose | Pre Necropsy |
| G6 | 35 | N | N | N | N | N |
| 36 | N | N | N | N | N | |
| 37 | N | N | N | N | N | |
| 38 | N | N | N | N | N | |
| 39 | N | N | N | N | N | |
| 40 | N | N | N | N | N | |
| G7 | 41 | N | N | N | N | N |
| 42 | N | N | N | N | N | |
| 43 | N | N | N | N | N | |
| 44 | N | N | N | N | N | |
| 45 | N | N | N | N | N | |
| 46 | N | N | N | N | N | |
| G8 | 47 | N | N | N | N | N |
| 48 | N | N | N | N | N | |
| 49 | N | N | N | N | N | |
| 50 | N | N | N | N | N | |
| 51 | N | N | N | N | N | |
| 52 | N | N | N | N | N | |
| G9 | 53 | N | N | N | N | N |
| 54 | N | N | N | N | N | |
| 55 | N | N | N | N | N | |
| 56 | N | N | N | N | N | |
| 57 | N | N | N | N | N | |
| 58 | N | N | N | N | N | |
| G10 | 59 | N | NA | N | N | N |
| 60 | N | NA | N | N | N | |
| 61 | N | NA | N | N | N | |
| 62 | N | NA | N | N | N | |
| 63 | N | NA | N | N | N | |
| 64 | N | NA | N | N | N | |
A#= Animal number; N= Normal, NA= Not Applicable; G6=Vehicle control: 0 mg/kg/day; G7=Synacinn™: 500 mg/kg/day; G8=Synacinn™: 1000 mg/kg/day; G9= Synacinn™: 2000 mg/kg/day; G10= Cyclophosphamide monohydrate: 25 mg/kg.